Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia

Autry, R. J.; Paugh, S. W.; Carter, R.; Shi, L.; Liu, J.; Ferguson, D.; Lau, C. E.; Bonten, E. J.; Yang, W.; McCorkle, J. R.; Beard, J. A.; Panetta, J. C.; Diedrich, J.; Crews, K..R.; Pei, D.; Coke, C. J.; Natarajan, S.; Khatamian, A.; Karol, S. E.; López López, Elixabet; Diouf, B.; Smith, C.; Gocho, Y.; Hagiwara, K.; Roberts, K. G.; Pounds, S.; Kornblau, S. M.; Stock, W.; Paietta, E. M.; Litzow, M. R.; Inaba, H.

View/Open

Postprint (8.435Mb)

Date

2020-03

Author

Autry, R. J.

Paugh, S. W.

Carter, R.

Shi, L.

Liu, J.

Ferguson, D.

Lau, C. E.

Bonten, E. J.

Yang, W.

McCorkle, J. R.

Beard, J. A.

Panetta, J. C.

Diedrich, J.

Crews, K..R.

Pei, D.

Coke, C. J.

Natarajan, S.

Khatamian, A.

Karol, S. E.

López López, Elixabet

Diouf, B.

Smith, C.

Gocho, Y.

Hagiwara, K.

Roberts, K. G.

Pounds, S.

Kornblau, S. M.

Stock, W.

Paietta, E. M.

Litzow, M. R.

Inaba, H.

Metadata

Show full item record

Estadisticas en RECOLECTA
(LA Referencia)

Nature Cancer 1(3) : 329-34 (2020)

URI

http://hdl.handle.net/10810/66935

Abstract

Identification of genomic and epigenomic determinants of drug resistance provides important insights for improving cancer treatment. Using agnostic genome-wide interrogation of mRNA and miRNA expression, DNA methylation, SNPs, CNAs and SNVs/Indels in primary human acute lymphoblastic leukemia cells, we identified 463 genomic features associated with glucocorticoid resistance. Gene-level aggregation identified 118 overlapping genes, 15 of which were confirmed by genome-wide CRISPR screen. Collectively, this identified 30 of 38 (79%) known glucocorticoid-resistance genes/miRNAs and all 38 known resistance pathways, while revealing 14 genes not previously associated with glucocorticoid-resistance. Single cell RNAseq and network-based transcriptomic modelling corroborated the top previously undiscovered gene, CELSR2. Manipulation of CELSR2 recapitulated glucocorticoid resistance in human leukemia cell lines and revealed a synergistic drug combination (prednisolone and venetoclax) that mitigated resistance in mouse xenograft models. These findings illustrate the power of an integrative genomic strategy for elucidating genes and pathways conferring drug resistance in cancer cells.

Collections

Artículos